Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Estefanía Alañón"'
Autor:
José M. Serra López-Matencio, Esther F. Vicente-Rabaneda, Estefanía Alañón, Ainhoa Aranguren Oyarzabal, Pedro Martínez Fleta, Santos Castañeda
Publikováno v:
Vaccines, Vol 11, Iss 12, p 1813 (2023)
The COVID-19 vaccination program has probably been the most complex and extensive project in history until now, which has been a challenge for all the people involved in the planning and management of this program. Patients with immune-mediated infla
Externí odkaz:
https://doaj.org/article/c627d2a03f4c423aa72f54395b6110fa
Autor:
Vicente Escudero-Vilaplana, Esther Ramírez-Herraiz, Nicolás Trovato-López, Estefanía Alañón-Plaza, María José Bellini, Ana Herranz-Alonso, José María Bellón-Cano, Alberto Morell-Baladrón, María Sanjurjo-Sáez
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 15, Iss 3 (2012)
Purpose. To evaluate the association between starting early treatment with anti-TNF and effectiveness as well as the possibility of applying therapeutic spacing in daily practice in patients with rheumatoid arthritis (RA). Methods. Observational, ret
Externí odkaz:
https://doaj.org/article/a1d0935878e244b99100752c46fae778
Autor:
José María, Serra López-Matencio, Ana Beatriz, Gago-Veiga, Manuel, Gómez, Estefanía, Alañón Plaza, Gina Paola, Mejía, Miguel Ángel, González-Gay, Santos, Castañeda
Publikováno v:
Expert Opinion on Biological Therapy. 22:707-716
In the few last years, a new family of drugs, anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), has been developed for migraine therapy. Anti-CGRP mAbs are highly effective, but the current limited experience with their use an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f1de01932f048dde617704ea4086790
https://doi.org/10.1080/14712598.2022.2072207
https://doi.org/10.1080/14712598.2022.2072207
Autor:
Santos Castañeda, José M. Serra López-Matencio, Valle Gómez García de Soria, Manuel Gómez, Cecilia Muñoz-Calleja, Estefanía Alañón-Plaza
Publikováno v:
Expert opinion on drug safety. 21(3)
Introduction In the last few years, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells, has been developed. CAR-T cells are highly effective at inhibiting antitumor activity, but they can cause a wide spectrum of unusual side effects. Ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9849d4cc19a9d17075ba812f14eb11
https://pubmed.ncbi.nlm.nih.gov/34519234
https://pubmed.ncbi.nlm.nih.gov/34519234
Autor:
Esther Ramírez-Herráiz, Nicolás Trovato-López, Vicente Escudero-Vilaplana, Estefanía Alañón-Plaza, Rosario García-Vicuña, Alberto Morell-Baladrón, María Sanjurjo-Sáez, Luis Carreño-Pérez
Publikováno v:
International Journal of Clinical Pharmacy. 37:808-814
Background Information on the use of ankylosing spondylitis (AS) therapies in clinical practice is a key factor in decision making, as more efficient treatments may involve substantial savings while maintaining the clinical benefits for the patient.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e5e8e94a2d4317e62a72d50105e2f1
https://doi.org/10.1007/s11096-015-0124-1
https://doi.org/10.1007/s11096-015-0124-1
Autor:
Esther, Ramírez-Herráiz, Vicente, Escudero-Vilaplana, Estefanía, Alañón-Plaza, Nicolás, Trovato-López, Ana, Herranz-Alonso, Alberto, Morell-Baladrón, María, Sanjurjo-Sáez
Publikováno v:
Clinical and experimental rheumatology. 31(4)
This retrospective, multicentre, observational study aimed to assess the mean annual doses and associated costs of three anti-tumour necrosis factor agents in daily clinical practice in rheumatoid arthritis patients, correlating these costs with dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aad8e63586dff3f225eb0db2cd497dfa
https://pubmed.ncbi.nlm.nih.gov/23710583
https://pubmed.ncbi.nlm.nih.gov/23710583
Autor:
Nicolás Trovato-López, Estefanía Alañón-Plaza, Vicente Escudero-Vilaplana, María José Bellini, María Sanjurjo-Sáez, Esther Ramírez-Herráiz, Ana Herranz-Alonso, Alberto Morell-Baladrón
Publikováno v:
European Journal of Hospital Pharmacy. 20:A144.2-A144
Background Achieving minimum clinically effective doses could improve the efficiency of treatment with anti-TNF. Purpose To evaluate the mean dose in ankylosing spondylitis (AS) patients treated with adalimumab (ADA), etanercept (ETN) or infliximab (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4acacd0c165219546e79cf7ee2dbd60f
https://doi.org/10.1136/ejhpharm-2013-000276.398
https://doi.org/10.1136/ejhpharm-2013-000276.398